Skip to main content

Table 2 Application of drugs during follow-up

From: Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban

Medicine Fondaparinux (n = 422) Enoxaparin (n = 453) P
Aspirin [n(%)] 419(99.3) 452(99.8) 0.567
Clopidogrel [n(%)] 338(80.1) 341(75.3) 0.088
ACE inhibitor or ARB [n(%)] 353(83.6) 379(83.7) 0.995
Calcium-channel blocker [n(%)] 69(16.4) 72(15.9) 0.854
Beta-blocker [n(%)] 360(85.3) 398(87.9) 0.268
Statin [n(%)] 397(94.0) 425(93.8) 0.874
  1. P < 0.05 was considered to indicate statistical significance